Transcriptomics

Dataset Information

0

Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer


ABSTRACT: Aerobic glycolysis (the Warburg effect) has been demonstrated to facilitate tumor progression by producing lactate, which has important roles as a proinflammatory and immunosuppressive mediator. However, how aerobic glycolysis is directly regulated is largely unknown. Here, we show that ectopic Zeb1 directly increases the transcriptional expression of HK2, PFKP and PKM2, which are glycolytic rate-determining enzymes, thus promoting the Warburg effect and breast cancer proliferation, migration, and chemoresistance in vitro and in vivo. In addition, Zeb1 exerts its biological effects to induce glycolytic activity in response to hypoxia via the PI3K/Akt/HIF-1α signaling axis, which contributes to fostering an immunosuppressive tumor microenvironment (TME). Mechanistically, breast cancer cells with ectopic Zeb1 expression produce lactate in the acidic tumor milieu to induce the alternatively activated macrophage M2-like phenotype through stimulation of the PKA/CREB signaling pathway. Clinically, the expression of Zeb1 is positively correlated with dysregulation of aerobic glycolysis, accumulation of M2-like tumor-associated macrophages (TAMs) and a poor prognosis in patients with breast cancer. In conclusion, these findings identify a Zeb1-dependent mechanism as a driver of breast cancer progression that acts by stimulating tumor-macrophage interplay, which could be a viable therapeutic target for the treatment of advanced human cancers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE189779 | GEO | 2022/03/09

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2016-03-08 | E-GEOD-76675 | biostudies-arrayexpress
2011-03-15 | E-GEOD-27309 | biostudies-arrayexpress
2016-03-08 | GSE76675 | GEO
2023-06-08 | GSE224648 | GEO
2023-06-08 | GSE202758 | GEO
2023-06-08 | GSE202757 | GEO
2024-04-25 | PXD048041 | Pride
2024-04-25 | PXD048012 | Pride
2024-04-25 | PXD048018 | Pride
2021-08-05 | PXD018410 | Pride